Patents Examined by Lawrence E. Crane
  • Patent number: 10117890
    Abstract: Methods for treating pain such as fibromyalgia, comprising administering to a subject in need thereof an effective amount of an adenosine analog, wherein the adenosine analog may be a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the adenosine analog for use in treating pain (e.g., fibromyalgia), optionally further comprising Substance P (SP), are also provided.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 6, 2018
    Assignee: Academia Sinica
    Inventors: Chih-Cheng Chen, Yun-Lian Lin, Jim-Min Fang, Yijuang Chern, Chia-Ching John Lin, Wei-Nan Chen, Chun-Jung Lin
  • Patent number: 10100302
    Abstract: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 16, 2018
    Assignee: HANDYLAB, INC.
    Inventors: Sundaresh N. Brahmasandra, Elizabeth Craig
  • Patent number: 10087208
    Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 2, 2018
    Assignee: AM CHEMICALS LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy
  • Patent number: 10071055
    Abstract: The present invention relates to a reducing or non-reducing polynucleotide polymer using a nucleotide from AMP, ADP, ATP, GMP, GDP, GTP, CMP, CDP and CTP, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and N-hydroxy-succinimide (NHS) for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 11, 2018
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Han Chang Kang, You Han Bae, Ha Na Cho
  • Patent number: 10072259
    Abstract: Compositions and techniques for the extraction, enrichment and isolation of nucleic acids from yeast in a whole blood sample using amine monomers are disclosed herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 11, 2018
    Assignee: Abbott Molecular Inc.
    Inventor: Gerard J. Gundling
  • Patent number: 10023861
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: July 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Patent number: 10022391
    Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
    Type: Grant
    Filed: April 24, 2016
    Date of Patent: July 17, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
  • Patent number: 10005810
    Abstract: Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of the compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 26, 2018
    Assignee: University College Cardiff Consultants Limited
    Inventors: Chirstopher McGuigan, Fabrizio Pertusati
  • Patent number: 10000521
    Abstract: In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 19, 2018
    Assignee: Nucorion Pharmaceuticals, Inc.
    Inventors: Zucai Suo, Vinod P. Vyavhare, David J. Taggart
  • Patent number: 9994604
    Abstract: The present invention relates to pyrazolotriazolyl nucleoside analogs, such as oligonucleotide comprising them, and uses in treatment of hepatitis C virus infections. Further the invention relates to a method for reducing gene expression in a cell comprising transfecting the cell with such an oligonucleotide.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 12, 2018
    Assignee: Bio-Lab Ltd.
    Inventors: Jean-Christophe Truffert, Myriam Lefoix, Jean Hildesheim, Tirtsa Kleinman
  • Patent number: 9988680
    Abstract: A composition for monitoring DNA damage includes a 3-ethynyl-5-nitroindolyl-2?-deoxyribose compound or pharmaceutically acceptable salt thereof and a detectable moiety with a click-reactive functional group that is complementary to the alkyne group of the compound.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee, Edward Motea
  • Patent number: 9963480
    Abstract: A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof:
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 8, 2018
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Xian Zhang, Sheng Bi, Yiping Gao, Hongyan Chen, Dezhong Wang, Yang Nan, Cang Zhang, Yuxiu Li, Di Zhang
  • Patent number: 9956243
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example: and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 1, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Patent number: 9944921
    Abstract: Compositions and techniques for the extraction, enrichment and isolation of nucleic acids from cellular source material using an ammonium hydroxide-based solution are disclosed herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 17, 2018
    Assignee: Abbott Molecular Inc.
    Inventor: Gerard J. Gundling
  • Patent number: 9914956
    Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: March 13, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Jim-Min Fang, Yih-Shyun E. Cheng, Charng-Sheng Tsai
  • Patent number: 9908914
    Abstract: Disclosed herein are methods of preparing a nucleoside analog (I) by a reaction that includes an intermediate (GG): Nucleoside analog (I) is useful in treating diseases and/or conditions such as viral infections.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: March 6, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman
  • Patent number: 9902752
    Abstract: The present invention is directed to a compound that can be used in the treatment of cancer. The compound is represented by formula (I) Further, X is In addition, R1 is selected from H, and substituted or unsubstituted cyclic terpene moieties; R7 and R8 are independently selected from C1 to C30 alkyl; n is an integer ranging 1 to 4; and a is an integer ranging from 1 to 20. Moreover, R2 is H; a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoamidite moiety; or —Y—X1 or —Y-L-Y1—X1, where Y and Y1 are independently from each other a single bond or a functional connecting moiety, X1 is a colloid-active compound, a fluorescence marker, or a polynucleotide moiety having up to 50 nucleotide residues.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: February 27, 2018
    Assignee: B. Braun Melsungen AG
    Inventors: Helmut Rosemeyer, Edith Malecki
  • Patent number: 9884886
    Abstract: The present invention relates to disulfide masked prodrug compounds of formula I, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione: W—P(V)LG??(Formula I), wherein P(V)LG is a pentavalent phosphorus leaving group; and W is: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. Once administered, the prodrug is metabolized in vivo into an active metabolite in a process termed bioactivation.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: February 6, 2018
    Assignee: Merck Sharp & Dohme
    Inventor: Gabor Butora
  • Patent number: 9879043
    Abstract: The present disclosure relates to the synthesis of non-natural analogs of S-adenosyl-L-methionine (SAM) and/or of Se-adenosyl-L-methionine (SeAM) by reacting a methionine analog and adenosine triphosphate (ATP) in the presence of at least one methionine adenosyltransferase (MAT), and to use thereof with downstream SAM and/or SeAM utilizing enzymes. The non-natural analogs of SAM and/or SeAM have the general formula: where X is S or Se, and R1 is an alkyl group.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 30, 2018
    Assignee: University of Kentucky Research Foundation
    Inventors: Jon Thorson, Tyler Huber, Jianjun Zhang, Shanteri Singh
  • Patent number: 9862741
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers. The compounds that useful for treating a neoplasm in mammalian subjects. The cytidine derivative dimer has the following general formula (I): where R1 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R2 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R3 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; R4 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; and R5 is —(CH2)n—, substituted —(CH2)n—, or —(CH2)n—X1—X2—, X1 being O or S, and X2 being —(CH2)n-Ph, pyrimidyl, pyranyl, imidazolyl, pyrazinyl, or pyridyl. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 9, 2018
    Assignees: CHANGZHOU PANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Hui-Juan Wang